S1207 – Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.
1. WHAT TYPE OF CANCER? WHAT STAGE?
Early Stage Breast Cancer (Stage I, II, and III)
2. WHO IS ELIGIBLE?
Women who are ER/PR+ but Her2-
3. HOW WILL I BE TREATED?
Women may also receive Everolimus (an mTOR inhibitor)
For Physicians: More information about this specific trial at clinicaltrials.gov